Combined therapy (intravitreal bevacizumab plus verteporfin photodynamic therapy) versus intravitreal bevacizumab monotherapy for choroidal neovascularization due to age-related macular degeneration: a 1-year follow-up study | Zendy

Sandro Saviano | Zendy; Pia Leon | Zendy; Alessandro Mangogna | Zendy; Daniele Tognetto | Zendy

Open Access

Combined therapy (intravitreal bevacizumab plus verteporfin photodynamic therapy) versus intravitreal bevacizumab monotherapy for choroidal neovascularization due to age-related macular degeneration: a 1-year follow-up study

Author(s) -

Sandro Saviano,

Pia Leon,

Alessandro Mangogna,

Daniele Tognetto

Publication year - 2016

Publication title -

digital journal of ophthalmology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.223

H-Index - 7

ISSN - 1542-8958

DOI - 10.5693/djo.01.2014.01.004

Subject(s) - verteporfin , macular degeneration , choroidal neovascularization , medicine , bevacizumab , photodynamic therapy , ophthalmology , combination therapy , surgery , chemotherapy , chemistry , organic chemistry

To assess the efficacy and safety of combined intravitreal bevacizumab and low-fluency-rate photodynamic therapy (PDT) in the treatment of choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD) and to compare it with intravitreal bevacizumab monotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research